Mayne Pharma’s FY20 Results Out; Posted A$92.8 Million Net Loss, Revenue Down 13%

August 21, 2020 01:03 PM AEST | By Team Kalkine Media

Google News:

Recent News

EUR/USD poised to rack up more gains as ECB and Fed rate paths set to...

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

US job growth in May tops forecasts, but Macquarie warns cracks are em...

Mayne Pharma Group Limited (ASX:MYX) releases its full-year results for FY20 (ended 30 June 2020), highlights are-

During FY20, Mayne reported revenues of almost A$457.0 million down by 13% on FY19
Reported EBITDA stood at A$80.3 million, down by 28% on FY19.
Net loss after tax reported at A$92.8 million led by intangible asset impairment linked largely with the generic business.
Generic Products performance stabilised in the 2^nd half of FY20 and Metrics Contract Services delivered strong revenue growth.
In the US, Mayne received US FDA filing acceptance for NEXTSTELLIS™ (E4/DRSP).
Prescriptions were down ~15% across the dermatology portfolio in April and May 2020 versus pcp.
Prescriptions of TOLSURA® also dropped during FY20 after increasing consistently across the first 9 months of FY20.

On 21 August 2020, the share price of MYX was trading at A$0.340 down by 2.857% at AEST 12:00 PM.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.